Synthace collaborates with MSD to develop biomanufacturing platform


Will use Synthace's high throughput methods and tools for a number of undisclosed molecules

Synthace, a London, UK-based synthetic biology company has entered into a new relationship with MSD (known as Merck & Co in the US and Canada).

The collaboration will use Synthace’s high throughput methods and tools to develop a biomanufacturing platform for a number of undisclosed molecules. The tie-up builds on a previous agreement with MSD initiated in 2014.

'We are delighted to extend our relationship with MSD, a recognised leader in bioprocess innovation within the pharma industry,' said Tim Fell, Chief Executive of Synthace.

Sign up for your free email newsletter

'This collaboration is focused on the rapid development of a high productivity, low cost of goods biomanufacturing process through the use of our next-generation approach to simultaneous genetic and process optimisation.'